Patients affected by severe genetic and orphan diseases Patients affected by severe genetic and orphan diseases Patients affected by severe genetic and orphan diseases

Transforming the
Lives of Patients

WITH SEVERE GENETIC AND ORPHAN DISEASES

We are developing next generation products based on the transformative potential of gene therapy to treat patients with severe genetic and orphan diseases. We have two clinical stage products in development for childhood cerebral adrenoleukodystrophy and beta-thalassemia/sickle cell disease, a preclinical oncology program in partnership with Celgene, a world-class team and a broadly applicable gene therapy platform READ MORE >>

career opportunities

We are growing and need great talent. We currently have lots of exciting opportunities, including the following positions:

Click here to apply

spotlight

March 27, 2014

bluebird bio Announces First Patient Transplanted in Phase 1/2 Northstar Study for the Treatment of Beta-Thalassemia

Read More

March 5, 2014

bluebird bio Reports Fiscal Year End 2013 Financial Results

Read More

February 26, 2014

bluebird bio to Present at the Cowen and Company Health Care Conference

Read More